Autoantibodies against p53 are associated with chromosome 17p deletions in chronic lymphocytic leukemia

Leukemia Research

Volumn 35, Issue 7, 2011, Pages 965-967

  Messmer, Bradley T ^a   Nour Omid, Talia S ^a   Ghia, Emanuela ^a   Sanchez, Ana B ^a   Kipps, Thomas J ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Autoantibodies; Cytogenetics; ELISA; Leukemia; Peptide; TP53

Indexed keywords

AUTOANTIBODY; PROTEIN P53 ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ARTICLE; CHROMOSOME 11Q; CHROMOSOME 13Q; CHROMOSOME 17P; CHROMOSOME DELETION; CHROMOSOME DELETION 13; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; GENE MUTATION; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; TRISOMY 12;

AUTOANTIBODIES; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 17; ENZYME-LINKED IMMUNOSORBENT ASSAY; HETEROZYGOTE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MUTATION; PEPTIDE FRAGMENTS; PROGNOSIS; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79958754212     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.04.009     Document Type: Article

References (13)

1. Dicker F., Herholz H., Schnittger S., Nakao A., Patten N., Wu L., et al. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia 2009, 23(1):117-124.
2. Rossi D., Cerri M., Deambrogi C., Sozzi E., Cresta S., Rasi S., et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res 2009, 15(3):995-1004.
3. Zenz T., Benner A., Dohner H., Stilgenbauer S. Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway. Cell Cycle 2008, 7(24):3810-3814.
4. Crawford L.V., Pim D.C., Bulbrook R.D. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 1982, 30(4):403-408.
5. Soussi T. p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res 2000, 60(7):1777-1788.
6. Mattioni M., Soddu S., Porrello A., D'Alessandro R., Spila A., Guadagni F. Serum anti-p53 antibodies as a useful marker for prognosis of gastric carcinoma. Int J Biol Markers 2007, 22(4):302-306.
7. Angelopoulou K., Yu H., Bharaj B., Giai M., Diamandis E.P. p53 gene mutation, tumor p53 protein overexpression, and serum p53 autoantibody generation in patients with breast cancer. Clin Biochem 2000, 33(1):53-62.
8. Portefaix J.M., Fanutti C., Granier C., Crapez E., Perham R., Grenier J., et al. Detection of anti-p53 antibodies by ELISA using p53 synthetic or phage-displayed peptides. J Immunol Methods 2002, 259(1-2):65-75.
9. Wrighton K.H., Prele C.M., Sunters A., Yeudall W.A. Aberrant p53 alters DNA damage checkpoints in response to cisplatin: downregulation of CDK expression and activity. Int J Cancer 2004, 112(5):760-770.
10. Zhong L., Coe S.P., Stromberg A.J., Khattar N.H., Jett J.R., Hirschowitz E.A. Profiling tumor-associated antibodies for early detection of non-small cell lung cancer. J Thorac Oncol 2006, 1(6):513-519.
11. Cho-Chung Y.S. Autoantibody biomarkers in the detection of cancer. Biochim Biophys Acta 2006, 1762(6):587-591.
12. Wang X., Yu J., Sreekumar A., Varambally S., Shen R., Giacherio D., et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005, 353(12):1224-1235.
13. Bradford T.J., Wang X., Chinnaiyan A.M. Cancer immunomics: using autoantibody signatures in the early detection of prostate cancer. Urol Oncol 2006, 24(3):237-242.